The Potential Impact of RNA Splicing Abnormalities on Immune Regulation in Endometrial Cancer

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2025 Mar 3

PMID 40032844

Authors

Minyue Cao

Jiayu Yan

Yan Ding

Yiqin Zhang

Yihan Sun

Genyi Jiang

Yanli Zhang

Bilan Li

Affiliations

Soon will be listed here.

Abstract

RNA splicing controls the post-transcriptional level of gene expression, allowing for the synthesis of many transcripts with various configurations and roles. Variations in RNA splicing regulatory factors, including splicing factors, signaling pathways, epigenetic modifications, and environmental factors, are typically the origin of tumor-associated splicing anomalies. Furthermore, thorough literature assessments on the intricate connection between tumor-related splicing dysregulation and tumor immunity are currently lacking. Therefore, we also thoroughly discuss putative targets associated with RNA splicing in endometrial cancer (EC) and the possible impacts of aberrant RNA splicing on the immune control of tumor cells and tumor microenvironment (TME), which contributes to enhancing the utilization of immunotherapy in the management of EC and offers an alternative viewpoint for the exploration of cancer therapies and plausible prognostic indicators.

References

Agra Almeida Quadros A, Li Z, Wang X, Ndayambaje I, Aryal S, Ramesh N . Cryptic splicing of stathmin-2 and UNC13A mRNAs is a pathological hallmark of TDP-43-associated Alzheimer's disease. Acta Neuropathol. 2024; 147(1):9. PMC: 10766724. DOI: 10.1007/s00401-023-02655-0. View

Lee D, Zhang J, Liu J, Gerstein M . Epigenome-based splicing prediction using a recurrent neural network. PLoS Comput Biol. 2020; 16(6):e1008006. PMC: 7343189. DOI: 10.1371/journal.pcbi.1008006. View

Bernard A, Hibos C, Richard C, Viltard E, Chevrier S, Lemoine S . The Tumor Microenvironment Impairs Th1 IFNγ Secretion through Alternative Splicing Modifications of Pre-mRNA. Cancer Immunol Res. 2021; 9(3):324-336. DOI: 10.1158/2326-6066.CIR-19-0679. View

Merlotti A, Sadacca B, Arribas Y, Ngoma M, Burbage M, Goudot C . Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer. Sci Immunol. 2023; 8(80):eabm6359. DOI: 10.1126/sciimmunol.abm6359. View

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

Tong A, Nguyen J, Lynch K . Differential expression of CD45 isoforms is controlled by the combined activity of basal and inducible splicing-regulatory elements in each of the variable exons. J Biol Chem. 2005; 280(46):38297-304. DOI: 10.1074/jbc.M508123200. View

Preussner M, Schreiner S, Hung L, Porstner M, Jack H, Benes V . HnRNP L and L-like cooperate in multiple-exon regulation of CD45 alternative splicing. Nucleic Acids Res. 2012; 40(12):5666-78. PMC: 3384337. DOI: 10.1093/nar/gks221. View

Huang D, Cai D, Chua R, Kemeny D, Wong S . Nitric-oxide synthase 2 interacts with CD74 and inhibits its cleavage by caspase during dendritic cell development. J Biol Chem. 2007; 283(3):1713-1722. DOI: 10.1074/jbc.M705998200. View

Bokhman J . Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1):10-7. DOI: 10.1016/0090-8258(83)90111-7. View

10.

Weg-Remers S, Ponta H, Herrlich P, Konig H . Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J. 2001; 20(15):4194-203. PMC: 149173. DOI: 10.1093/emboj/20.15.4194. View

11.

Tian C, Zhang Y, Tong Y, Kock K, Sim D, Liu F . Single-cell RNA sequencing of peripheral blood links cell-type-specific regulation of splicing to autoimmune and inflammatory diseases. Nat Genet. 2024; 56(12):2739-2752. PMC: 11631754. DOI: 10.1038/s41588-024-02019-8. View

12.

Meininger I, Griesbach R, Hu D, Gehring T, Seeholzer T, Bertossi A . Alternative splicing of MALT1 controls signalling and activation of CD4(+) T cells. Nat Commun. 2016; 7:11292. PMC: 4832065. DOI: 10.1038/ncomms11292. View

13.

Geng G, Xu C, Peng N, Li Y, Liu J, Wu J . PTBP1 is necessary for dendritic cells to regulate T-cell homeostasis and antitumour immunity. Immunology. 2021; 163(1):74-85. PMC: 8044338. DOI: 10.1111/imm.13304. View

14.

Indraccolo S, Minuzzo S, Zamarchi R, Calderazzo F, Piovan E, Amadori A . Alternatively spliced forms of Igalpha and Igbeta prevent B cell receptor expression on the cell surface. Eur J Immunol. 2002; 32(6):1530-40. DOI: 10.1002/1521-4141(200206)32:6<1530::AID-IMMU1530>3.0.CO;2-#. View

15.

Kornblihtt A . Epigenetics at the base of alternative splicing changes that promote colorectal cancer. J Clin Invest. 2017; 127(9):3281-3283. PMC: 5669579. DOI: 10.1172/JCI96497. View

16.

Takeo K, Kawai T, Nishida K, Masuda K, Teshima-Kondo S, Tanahashi T . Oxidative stress-induced alternative splicing of transformer 2beta (SFRS10) and CD44 pre-mRNAs in gastric epithelial cells. Am J Physiol Cell Physiol. 2009; 297(2):C330-8. DOI: 10.1152/ajpcell.00009.2009. View

17.

Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S . Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019; 216(4):982-1000. PMC: 6446862. DOI: 10.1084/jem.20180870. View

18.

De Rosa V, Galgani M, Porcellini A, Colamatteo A, Santopaolo M, Zuchegna C . Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat Immunol. 2015; 16(11):1174-84. PMC: 4868085. DOI: 10.1038/ni.3269. View

19.

Jonsson J, Zhai Q, Schwartz S, Kajitani N . hnRNP H controls alternative splicing of human papillomavirus type 16 E1, E6, E7, and E6^E7 mRNAs via GGG motifs. J Virol. 2024; 98(10):e0095124. PMC: 11494879. DOI: 10.1128/jvi.00951-24. View

20.

Zhang L, Fritah S, Nazarov P, Kaoma T, Van Dyck E . Impact of IDH Mutations, the 1p/19q Co-Deletion and the G-CIMP Status on Alternative Splicing in Diffuse Gliomas. Int J Mol Sci. 2023; 24(12). PMC: 10297931. DOI: 10.3390/ijms24129825. View